Naratriptan Hexal (Naratriptan)

Naratriptan acts as a selective agonist at serotonin 5‑HT1B and 5‑HT1D receptors. By stimulating these receptors, it narrows dilated cranial blood vessels and blocks the release of pain‑triggering neuropeptides, interrupting the migraine pain pathway.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s medical history, severity of migraine, and response to therapy. Patients should follow the prescriber’s instructions exactly.

Safety data for Naratriptan in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and consider alternative treatments when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naratriptan belongs to the triptan class, which is generally more migraine‑specific than non‑specific analgesics such as NSAIDs. Compared with other triptans, Naratriptan has a longer half‑life, offering a slightly extended duration of relief, but individual response varies.

Store Naratriptan tablets at room temperature, below 25 °C, in the original packaging. Keep the container tightly closed, protect from moisture and direct sunlight, and discard any tablets that appear discoloured or damaged.

Naratriptan Hexal is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably at the first sign of a migraine attack. Do not crush, chew, or split the tablet unless directed by a healthcare professional.

Serious risks include chest pain or tightness, severe hypertension, and serotonin syndrome—especially when combined with other serotonergic drugs. Patients should seek immediate medical attention if they experience any of these symptoms.

Naratriptan is contraindicated in patients with a history of coronary artery disease, uncontrolled hypertension, peripheral vascular disease, or known hypersensitivity to the drug. It should also be avoided in individuals taking ergotamine-containing medications.